Other News

Boston Scientific Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2018

MARLBOROUGH, Mass., Jan. 8, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE:   BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018. This represents growth of approximately 6.3 percent on a reported basis, approximately 8.2 percent on an operational1 basis and approximately 7.0 percent on an organic2 basis, […]

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that as part of the Company’s commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor […]

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance. Preliminary, unaudited revenue for fourth quarter 2018 is expected to be […]

Intact Vascular Announces Launch of the Tack Endovascular System® in the EU and First Commercial Use in Germany

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® in multiple hospitals within Germany. A novel therapy for dissection repair following balloon angioplasty, the Tack® implant is a first-of-its kind device for patients with peripheral […]

Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million. Revenue for the full year ended December 31, 2018 is expected […]

New Heart Biometric Technology Confirms Your Identity and Measures Your Health via Advanced Auto Steering Wheel and Wearable Technology

LAS VEGAS–(BUSINESS WIRE)–EKG biometrics innovator B-Secur officially introduced its collection of powerful EKG authentication and wellness algorithms, HeartKey, at the 2019 Pepcom Digital Experience! This technology, with applications in the automotive and wearable technology industries, will soon be available in vehicles, top fitness trackers and smart wear of the future […]

Cardiovascular Systems, Inc. Announces Preliminary Fiscal 2019 Second-Quarter Revenues of $60.2 Million

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced preliminary and unaudited revenue results for its fiscal second quarter, ended December 31, 2018. Second-quarter revenues are expected to be […]

Microbot Medical Announces FDA Pre-Submission Milestones for 2019

HINGHAM, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq CM: MBOT) announced today anticipated operational and product milestones, including pivotal pre-clinical study and FDA pre-submission milestones, for 2019. The progress and successful execution of key objectives in 2018, which included, among other things, Microbot’s successful completion of […]

Merit Medical to Present at Needham Growth Conference

SOUTH JORDAN, Utah, Jan. 07, 2019 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate at the 21stAnnual Needham […]

Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment

NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. Mesoblast Chief […]